The usage of hormone alternative remedy (HRT) doesn’t have an antagonistic impact on breast most cancers danger in line with outcomes from an ongoing examine inspecting sufferers at excessive danger for growing each breast and ovarian most cancers with the BRCA1 or BRCA2 variants. This examine collects affected person knowledge by means of questionnaires each two years.
Knowledge have been offered on the
“We’re not likely ready to conduct a medical trial of HRT, so as a substitute we thought we’d take a extra matched method the place we’d match girls who did and didn’t provoke HRT after surgical procedure,” mentioned Kotsopoulos.
The cumulative incidence (CI) of breast most cancers amongst BRCA carriers by an any HRT use was considerably decrease in sufferers who did use HRT in comparison with sufferers who didn’t (24.5% versus 42.9%).
“Use of any kind of [HRT] was inversely related to danger,” defined Kotsopoulos. “Then after we stratified by estrogen alone, which is utilized in girls who don’t have uteruses, after which within the estrogen and progestin mixture, utilized in girls who do have a uterus, we see that the inverse affiliation was restricted to girls who used [estrogen] alone. The patterns have been related whether or not we checked out BRCA1 or BRCA2.”
A complete of 676 matched pairs have been included within the evaluation. The variety of sufferers uncovered to any HRT use with both BRCA variant was 87, and the variety of unexposed sufferers was 128.
In sufferers with an estrogen-alone formulation, there was statistically important affiliation with diminished mortality. In sufferers with an estrogen plus progestin formulation, a statistically important danger discount was not noticed.
Kotsopoulos famous that the variety of sufferers with BRCA2 have been too few to ship sturdy outcomes.
Examine Rationale
The analysis addresses a essential medical problem for girls with a pathogenic variant within the BRCA1 or BRCA2 genes who’ve a historical past of breast most cancers.
The usual medical steerage contraindicates using menopausal HRT for any lady with a private historical past of breast most cancers.
This difficulty is especially essential for BRCA carriers as a consequence of two key elements: an inclination to develop breast most cancers at an early age, and the widespread advice to endure risk-reducing oophorectomy previous to pure menopause, which induces menopausal signs.
The examine aimed to prospectively analyze the affiliation between menopausal HRT use after a breast most cancers analysis in BRCA carriers and the following danger of demise.
Analysis Methodology
The examine was a potential evaluation performed utilizing knowledge from a longitudinal examine cohort.
The evaluation included BRCA carriers with a confirmed analysis of breast most cancers who had no historical past of different cancers and had not used menopausal HRT previous to their breast most cancers analysis.
A matched-pair design was employed to manage for confounding variables. Every menopausal HRT consumer was matched to a nonuser based mostly on 12 months of start, age at breast most cancers analysis, and coverings obtained. This resulted in a complete examine measurement of 676 matched pairs.
“To summarize, I feel the general conclusion is that we noticed no antagonistic occasion [HRT] on BRCA breast most cancers danger. Estrogen alone was related to a decrease danger, no matter route and sort. We noticed no elevated dangers with the mix remedy,” mentioned Kotsopoulos.
Kotsopoulos additionally acknowledged the constraints of the examine, together with small strata, not stratifying by tumor receptor standing, and the necessity for an extended follow-up.
References
- “Menopausal hormone remedy and the danger of breast most cancers in girls with pathogenic variant in BRCA1 or BRCA2,” by Kotsopoulos J. Press briefing. San Antonio Breast Most cancers Symposium. December 12, 2025.
- “Menopausal hormone remedy after a analysis of breast most cancers in girls with a BRCA pathogenic variant and danger of demise,” by Kotsopoulos J, Seca M, Lubinski J, et al. Revealed Might 28, 2025. Accessed December 11, 2025. J Clin Oncol 43.
For extra information on most cancers updates, analysis and schooling, don’t overlook to
